Can Antidepressants Influence the Course of Inflammatory Bowel Disease? The Current State of Research

European Gastroenterology & Hepatology Review, 2009;5:48-53

Abstract

A previous systematic review conducted in 2006 indicated that antidepressants may have the potential to improve the course of inflammatory bowel disease (IBD). The current study is an update of this review, aiming to identify and summarise available data on the effect of antidepressants on IBD activity published between 2006 and 2009. Electronic databases were searched to identify all relevant publications issued between 2006 and 2009 in English. Four studies met the inclusion criteria: three randomised controlled trials (RCTs) and one qualitative interview study. Six other papers with relevance to the subject that did not meet inclusion criteria were also identified. Desipramine was found to reduce vulnerability to colitis and to improve all examined inflammatory markers in the three animal RCTs; fluoxetine was found to protect against colitis in one RCT. Overall, the sudies suggest a positive impact of antidepressants on inflammation in IBD. However, good-quality human data are lacking and more RCTs are needed.
Keywords
Inflammatory bowel disease, antidepressants, anti-inflammatory, depression, desipramine, fluoxetine
Disclosure The authors have no conflicts of interest to declare.
Received: June 11, 2009 Accepted June 30, 2009
Correspondence: Antonina Mikocka-Walus, Department of Epidemiology and Preventive Medicine, Monash University, 89 Commercial Rd, Melbourne 3004, VIC, Australia. E: antonina.mikocka-walus@med.monash.edu.au

Inflammatory bowel disease (IBD) is a generic term used to describe a group of chronic and relapsing inflammatory disorders of the gastrointestinal tract, of which Crohn’s disease (CD) and ulcerative colitis (UC) are the most common. IBD is characterised by an inappropriate immune response that causes characteristic inflammatory lesions in the gut wall. The aetiology of IBD is unknown. Nonetheless, genetic, immune and environmental factors have all been implicated in its causation. Interestingly, stress has been found to lead to exacerbation of the disease.1

IBD is at present an incurable condition and its course is unpredictable. As the disease is usually diagnosed in young adults, sufferers must often cope with their disease for many years. Their quality of life and psychosocial wellbeing may be profoundly impaired as a consequence of systemic symptoms, surgery (such as installing a stoma), medication side effects and highly prevalent fatigue.2

IBD is often associated with irritable bowel syndrome (IBS).3 Up to 60% of IBD patients in remission continue to suffer symptoms of IBS.4 For these patients, quality of life and psychosocial wellbeing remain impaired regardless of whether IBD is active or quiescent. Furthermore, in population-based studies more than 50% of IBS patients have reported psychiatric symptoms.5 Thus, anxiety and depression in patients with IBD may be partly explained by co-existent IBS. In view of the above findings, it is not surprising that the rate of anxiety and depression in patients with IBD is around 30% during remission6 and as much as 70% during relapse.7

References:
1. Mawdsley JE, Macey MG, Feakins RM, et al., The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis, Gastroenterology, 2006;131(2):410–19. 2. Minderhoud IM, Oldenburg B, van Dam PS, et al., High prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiency, Am J Gastroenterol, 2003;98(5):1088–93. 3. Farrokhyar F, Marshall JK, Easterbrook B, Irvine EJ, Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health, Inflamm Bowel Dis, 2006;12(1):38–46. 4. Simren M, Axelsson J, Gillberg R, et al., Quality of Life in Inflammatory Bowel Disease in Remission: The Impact of IBS-Like Symptoms and Associated Psychological Factors, Am J Gastroenterol, 2002;97(2):389–96. 5. Hillila MT, Siivola MT, Farkkila MA, Comorbidity and use of health-care services among irritable bowel syndrome sufferers, Scand J Gastroenterol, 2007;42(7):799-80–. 6. Mittermaier C, Dejaco C, Waldhoer T, et al., Impact of Depressive Mood on Relapse in Patients With Inflammatory Bowel Disease: A Prospective 18-Month Follow-Up Study, Psychosom Med, 2004;66(1):79–84. 7. Addolorato G, Capristo E, Stefanini GF, Gasbarrini G, Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status, Scan J Gastroenterol, 1997;32(10):1013–21. 8. von Wietersheim J, Kessler H, Psychotherapy with chronic inflammatory bowel disease patients: a review, Inflamm Bowel Dis, 2006;12(12):1175–84. 9. Szuster-Ciesielska A, Tustanowska-Stachura A, Slotwinska M, et al., In vitro immunoregulatory effects of antidepressants in healthy volunteers, Pol J Pharmacol, 2003;55(3):353–62. 10. Varghese AK, Verdu EF, Bercik P, et al., Antidepressants attenuate increased susceptibility to colitis in a murine model of depression, Gastroenterology, 2006;130(6):1743–53. 11. Mikocka-Walus AA, Turnbull DA, Moulding NT, et al., Antidepressants and inflammatory bowel disease: a systematic review, Clin Pract Epidemol Ment Health, 2006;2(1):24. 12. Ghia JE, Blennerhassett P, Collins SM, Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression, J Clin Invest, 2008;118(6):2209–18. 13. Guemei AA, El Din NM, Baraka AM, El Said Darwish I, Do desipramine [10,11-dihydro-5-[3-(methylamino) propyl]- 5H-dibenz[b,f]azepine monohydrochloride] and fluoxetine [N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-propan- 1-amine] ameliorate the extent of colonic damage induced by acetic acid in rats?, J Pharmacol Exp Ther, 2008;327(3):846–50. 14. Mikocka-Walus A, Turnbull D, Moulding N, et al., “It doesn’t do any harm, but patients feel better”: a qualitative exploratory study on gastroenterologists’ perspectives on the role of antidepressants in inflammatory bowel disease, BMC Gastroenterology, 2007;7(1):38. 15. Bechade D, Carmoi T, Bonnefoy S, et al., Microscopic colitis associated with celiac disease probably triggered by the administration of venlafaxine, Rev Med Interne, 2009;30(1):74–7. 16. Fuller-Thomson E, Sulman J, Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys, Inflamm Bowel Dis, 2006;12(8):697–707. 17. Shen B, Fazio VW, Remzi FH, et al., Risk factors for diseases of ileal pouch-anal anastomosis after restorative proctocolectomy for ulcerative colitis, Clin Gastroenterol Hepatol, 2006;4(1):81–9, quiz 2–3. 18. Brustolim D, Ribeiro-dos-Santos R, Kast RE, et al., A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice, Int Immunopharmacol, 2006;6(6):903–7. 19. Rook GA, Lowry CA, The hygiene hypothesis and psychiatric disorders, Trends Immunol, 2008;29(4):150–58. 20. Fernandez-Banares F, Esteve M, Espinos JC, et al., Drug consumption and the risk of microscopic colitis, Am J Gastroenterol, 2007;102(2):324–30. 21. Kulmatycki KM, Jamali F, Drug disease interactions: role of inflammatory mediators in pain and variability in analgesic drug response, J Pharm Pharm Sci, 2007;10(4):554–66. 22. Eller T, Vasar V, Shlik J, Maron E, Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder, Prog Neuropsychopharmacol Biol Psychiatry, 2008;32(2):445–50. 23. Kubera M, Kenis G, Bosmans E, et al., Stimulatory effect of antidepressants on the production of IL-6, Int Immunopharmacol, 2004;4(2):185–92. 24. Kubera M, Lin AH, Kenis G, et al., Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio, J Clin Psychopharmacol, 2001;21(2):199–206. 25. Maes M, Delange J, Ranjan R, et al., Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs, Psychiatry Res, 1997;66(1):1–11. 26. Sluzewska A, Rybakowski JK, Laciak M, et al., Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine, Ann N Y Acad Sci, 199521;762: 474–6. 27. Abdel-Salam OM, Baiuomy AR, Arbid MS, Studies on the anti-inflammatory effect of fluoxetine in the rat, Pharmacol Res, 2004;49(2):119–31. 28. Abdel-Salam OM, Nofal SM, El-Shenawy SM, Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat, Pharmacol Res, 2003;48(2):157–65. 29. Takahashi T, Morinobu S, Iwamoto Y, Yamawaki S, Effect of paroxetine on enhanced contextual fear induced by single prolonged stress in rats, Psychopharmacology (Berl), 2006;189(2):165–73. 30. Dazzi L, Vacca G, Ladu S,et al., Long-term treatment with antidepressant drugs reduces the sensitivity of cortical cholinergic neurons to the activating actions of stress and the anxiogenic drug FG 7142, Neuropharmacology, 2001;41(2):229–37. 31. Kubera M, Symbirtsev A, Basta-Kaim A, et al., Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression, Pol J Pharmacol, 1996;48(5):503–6. 32. Leonard BE, The immune system, depression and the action of antidepressants, Prog Neuropsychopharmacol Biol Psychiatry, 2001;25(4):767–80. 33. van West D, Maes M, Activation of the inflammatory response system: A new look at the etiopathogenesis of major depression, Neuro Endocrinol Lett, 1999;20(1–2):11–17. 34. Capuron L, Ravaud A, Dantzer R, Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy, J Clin Oncol, 2000;18(10): 2143–51. 35. Maddock C, Baita A, Orru MG, et al., Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms, J Psychopharmacol, 2004;18(1):41–6. 36. Zorrilla EP, Luborsky L, McKay JR, et al., The relationship of depression and stressors to immunological assays: a meta-analytic review, Brain Behav Immun, 2001;15(3): 199–226. 37. Schiepers OJ, Wichers MC, Maes M, Cytokines and major depression, Prog Neuropsychopharmacol Biol Psychiatry, 2005;29(2):201–17. 38. Roumestan C, Michel A, Bichon F, et al., Anti-inflammatory properties of desipramine and fluoxetine, Respir Res, 2007;8(1):35. 39. Lichtenstein GR, Bala M, Han C, et al., Infliximab improves quality of life in patients with Crohn’s disease, Inflamm Bowel Dis, 2002;8(4):237–43. 40. Taler M, Bar M, Korob I, et al., Evidence for an inhibitory immunomodulatory effect of selected antidepressants on rat splenocytes: possible relevance to depression and hyperactive-immune disorders, Int Immunopharmacol, 2008;8(4):526–33. 41. Malinin A, Oshrine B, Serebruany V, Treatment with selective serotonin reuptake inhibitors for enhancing wound healing, Med Hypotheses, 2004;63(1):103–9.